HC Wainwright Has Positive Forecast for CLDX FY2025 Earnings

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Research analysts at HC Wainwright raised their FY2025 earnings per share (EPS) estimates for shares of Celldex Therapeutics in a research report issued on Wednesday, November 20th. HC Wainwright analyst J. Pantginis now forecasts that the biopharmaceutical company will post earnings of ($2.99) per share for the year, up from their previous forecast of ($3.02). HC Wainwright currently has a "Buy" rating and a $80.00 target price on the stock. The consensus estimate for Celldex Therapeutics' current full-year earnings is ($2.45) per share.

Other equities research analysts have also recently issued reports about the stock. Wolfe Research cut shares of Celldex Therapeutics from an "outperform" rating to a "peer perform" rating in a research report on Friday, September 27th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research note on Monday, September 16th. Citigroup assumed coverage on shares of Celldex Therapeutics in a research note on Monday, October 7th. They issued a "buy" rating and a $70.00 price target on the stock. The Goldman Sachs Group began coverage on shares of Celldex Therapeutics in a research note on Monday, September 30th. They set a "neutral" rating and a $45.00 price objective on the stock. Finally, Wells Fargo & Company raised shares of Celldex Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Thursday, September 26th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Celldex Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $62.25.

Celldex Therapeutics Stock Up 3.1 %

CLDX traded up $0.80 during trading on Friday, hitting $27.02. The company had a trading volume of 691,020 shares, compared to its average volume of 876,333. The company has a market capitalization of $1.79 billion, a PE ratio of -10.24 and a beta of 1.60. Celldex Therapeutics has a one year low of $22.93 and a one year high of $53.18. The firm's 50-day moving average price is $30.56 and its 200 day moving average price is $35.02.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in CLDX. Vanguard Group Inc. increased its holdings in shares of Celldex Therapeutics by 19.8% during the first quarter. Vanguard Group Inc. now owns 3,650,582 shares of the biopharmaceutical company's stock worth $153,215,000 after purchasing an additional 604,251 shares during the period. Ameritas Investment Partners Inc. increased its holdings in shares of Celldex Therapeutics by 34.3% during the first quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company's stock worth $260,000 after purchasing an additional 1,582 shares during the period. American International Group Inc. increased its holdings in shares of Celldex Therapeutics by 32.6% during the first quarter. American International Group Inc. now owns 30,629 shares of the biopharmaceutical company's stock worth $1,285,000 after purchasing an additional 7,535 shares during the period. CANADA LIFE ASSURANCE Co increased its holdings in shares of Celldex Therapeutics by 26.4% during the first quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company's stock worth $192,000 after purchasing an additional 955 shares during the period. Finally, Magnetar Financial LLC bought a new position in shares of Celldex Therapeutics during the first quarter worth approximately $452,000.

Insider Buying and Selling at Celldex Therapeutics

In related news, CEO Anthony S. Marucci purchased 11,500 shares of the stock in a transaction on Monday, November 11th. The shares were purchased at an average cost of $26.82 per share, with a total value of $308,430.00. Following the acquisition, the chief executive officer now directly owns 40,284 shares in the company, valued at $1,080,416.88. The trade was a 39.95 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 3.80% of the company's stock.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.